Vi aspettiamo oggi alle 16.00 CET per un nuovo imperdibile appuntamento dei MITICI Lunedì 🎯🧬#ovariancancer #MITOgroup #JC

We can end #cervicalcancer!💪🏽 ✔️Know the signs and symptoms ✔️Get vaccinated against HPV ✔️Get screened ✔️Spread the word! #CervicalCancerAwernessMonth #HPVvaccine #HPVtest 🌸🌷🌸 Pedro T Ramirez Arthur_HC_Hsu Ane Gerda Z Eriksson MD PhD Aarthi S Jayraj Andreina Fernandes IJGC Fellows ESGO

FDA approves elacestrant, oral SERD, for ESR1-mutated ER+ metastatic breast cancer, based on phase 3 EMERALD clinical trial. Last endocrine therapy approved was ~ 20 years ago. #bcsm OncoAlert Link to article and label: accessdata.fda.gov/drugsatfda_doc… ascopubs.org/doi/pdf/10.120…

February 4th 👉 #WorldCancerDay & for all patients #CloseTheCareGap Union for International #CancerControl

You don't want to miss this 👇 Join us virtually on Feb 13th, 14.00 CET to discover the power of AI in pathology Jakob Nikolas Kather @chiaralöffler Sandro pignata #miticilunedì #MITO #gynaeonc

Carbotaxolo e avelumab upfront per pazienti con cancro dell'endometrio: luci ed ombre del MITO END-3 tinyurl.com/2jbly6v9

Sessions from #ESMOGynae23 are still available on the virtual platform - so if you missed a great scientific or educational moment from the programme head over here 🔗 ow.ly/yMAS50N2FLT #ovariancancer #cervicalcancer #endometrialcancer #GynCSM #gynaecologicalcancers

#RareDiseaseDay: #RareCancers have specific challenges, incl. late/incorrect diagnosis, access to suitable tx/expertise, & clinical study difficulties. Cancers in AYAs are rare: paper reveals data on cancer burden in this population. ow.ly/W0mm50N4iP4 #AYACSM #AYAcancer

🔥Finally out🔥! Increadibly grateful for the opportunity to work with (and learn from❗️) amazing researchers Team McNeish Lab Susana Banerjee zhao cheng Darren Ennis Hasan Mirza & all authors and for the support from ESMO - Eur. Oncology 👇

La malattia di Paget vulvare è una rarissima forma di adenocarcinoma cutaneo vulvare tipica dell'età post-menopausale. Pubblicata una review del gruppo MITO Tumori Rari: mdpi.com/2072-6694/15/6… #oncology #paget #vulvarpaget #oncogynae #oncology #wearemito

📣Press-release: the #NataLEE trial met its 1️⃣endpoint at interim analysis demonstrating ⬆️IDFS with adjuvant #ribociclib + ET in HR+/HER2-neg early #breastcancer @oncoalert novartis.com/news/media-rel…

📣What a day! 💥 2 PIII trials: RUBY trial ➡️ practice changing results in #endometrialcancer What a terrific #ESMOVirtualPlenary ✨ NATALEE trial ➡️ met the primary EP of iDFS in #breastcancer in #pressrelease Waiting 4 results 🔜 ESMO - Eur. Oncology AACR #immunotherapy #precisiononcology

📢 Prognostic evaluation in patients with #advancedcancer in the last months of life: ESMO Clinical Practice Guideline. Prognostication and communication algorithm also included. ow.ly/tifo50NFMFG #PallOnc ESMO Open G Curigliano MD PhD Sébastien Moine

ESMO Advance Course on Precision Oncology. Excellent course!! Fantastic speakers and very engaged attendees. Thanks to ESMO for promoting high-level educational opportunities ESMO - Eur. Oncology Benjamin Besse Lizza Hendriks

🏃🏻‍♀️🏃🏻‍♂️ Avui l'equip #Running4Research de VHIO ens ha representat a la #cursadelamerce 🥇 Gràcies Nadia Saoudi González, Carolina Ortiz, @sharevega, @paliamalia, @jdassaf i Roberta Mazzeo per lluir la 🎽 VHIO ‼️ #ResisOncoVH #LaMerce

Moving from the simplistic definition of #ESR1 and #PIK3CA mutated metastatic #BreastCancer to a more granular resolution of single codon variants thanks to #ctDNA and #LiquidBiopsy for a more precise biological and clinical profiling of #MBC …ast-cancer-research.biomedcentral.com/articles/10.11…

Il 16 e 17 novembre a Pordenone Fiere torniamo a parlare di Gineco-Oncologia con esperti nazionali ed internazionali sul palco di BIG ecm.meetingsrl.eu/BIG2023/defaul… Non mancate

📌Il 16 e 17 novembre, a Pordenone Fiere, è in programma ‘BIG - Breakthrough in Gynaecologic Oncology. Ricerca, diagnostica e trattamento dei tumori ginecologici’ 📌Qui il programma e il link per iscriversi al corso, in presenza o in modalità webinar 👉ecm.meetingsrl.eu/BIG2023/default

Melanoma patients treated with systemic anti cancer therapy in the End-of-life (EoL) are more frequently hospitalized due to adverse event with higher cost and delayed palliative care referral. Take a look at the data presented at  #ESMO2023 Università di Udine ESMO - Eur. Oncology

We are thrilled to announce a new #ESMOVirtualPlenary presenting the latest research in #cervicalcancer. This edition brings the promising primary results from the BEATcc trial. ⏰ 3 Nov, 18:30 CET Full programme: ow.ly/eqsc50Q0WGY GEICO-Spanish Gynaecological Cancer Research Group Ray-Coquard Isabelle #GYNSM